A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

IRRAS Announces First Patient Treatments at Mount Sinai Health System in New York as Part of the DIVE Study

IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the initial patient treatments with the company’s IRRAflow system within Mount Sinai Health System in New York, NY, one of the United States’ largest and most respected hospital groups.

Thus far, two patients suffering from intraventricular hemorrhage (IVH) have been enrolled in the Deployment of Irrigating Intraventricular Catheter System (DIVE) clinical trial for patients. The DIVE study will assess the IRRAflow system’s ability to more effectively treat patients experiencing IVH than traditional treatment with an external ventricular drain (EVD).

The DIVE study is a retrospective and prospective cohort, controlled, single-center, phase 1 study with a primary objective of evaluating the safety and radiographic outcomes associated with using IRRAS’ IRRAflow system compared to the current standard of care with external ventricular drains.  Dr. Christopher Kellner, Assistant Professor of Neurosurgery and Director of the Intracerebral Hemorrhage program at Mount Sinai, is the Principal Investigator of the study, which will compare retrospective EVD data from Mount Sinai Hospital and Mount Sinai West Hospital to prospective data collected from future patients treated with IRRAflow in up to 140 patients (70 EVD versus 70 IRRAflow).

“We are excited to enroll our first patients in the DIVE study,” said Dr. Kellner. “We believe that the combination of irrigation and drainage has the potential to be a more efficient and cost-effective means to treat intraventricular hemorrhage than traditional passive drainage. Our first patient was successfully treated in just 67 hours, a significant reduction from our historic data for ICU and hospital length of stay.  This study will continue to enroll patients and assess outcomes.”

“Our growing partnership with Mount Sinai is another exciting step toward IRRAS becoming a leader in the treatment of intracranial bleeding,” said Will Martin, President and CEO of IRRAS.  “Working closely with such a prestigious institution and closely tracking the outcomes of their patients within the DIVE study will be an important piece of the growing pool of clinical evidence to support improved outcomes with IRRAflow for this critically ill group of patients.”

The Mount Sinai Health System is an internationally recognized leader in clinical neurosurgery, neurosurgery education, and neurosurgery research. For 2021-2022, Neurosurgery and Neurology at The Mount Sinai Hospital rank 9th in the United States, according to U.S. News and World Report.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy